ClinConnect ClinConnect Logo
Search / Trial NCT05335603

An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis

Launched by UNIVERSITY OF COPENHAGEN · Apr 12, 2022

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

Non Alcoholic Fatty Liver Disease Non Alcoholic Steatohepatitis Steatosis Autoimmune Hepatitis Primary Biliary Cholangitis Primary Sclerosing Cholangitis Haemochromatosis Alfa 1 Antitrypsin Deficiency Chronic Pancreatitis Chronic Liver Disease Inflammatory Bowel Disease Omics Mass Spectrometry

ClinConnect Summary

This clinical trial is studying patients with chronic liver diseases that are linked to a condition called hepatic steatosis, which is the buildup of fat in the liver. This buildup can lead to serious problems like inflammation, scarring, and even liver failure. The researchers want to learn more about these liver diseases to help find better ways to diagnose and treat them. They are looking for adult patients aged 18 and older who may have conditions such as non-alcoholic fatty liver disease, autoimmune hepatitis, or hereditary hemochromatosis, among others.

Participants in the study will undergo tests, including a liver biopsy, which is a procedure to take a small sample of liver tissue for examination. By understanding the specific characteristics of these liver conditions, the study hopes to identify important markers that can help doctors in the future. If you or someone you know has a chronic liver disease and is interested in participating, this trial could provide valuable insights into better care and treatment options.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adult patients/healthy control participants (age 18 or above) who can give their informed consent
  • * Suspected liver disease:
  • non-alcoholic steatohepatitis
  • alcoholic steatohepatitis
  • autoimmune hepatitis
  • primary biliary cholangitis
  • primary sclerosing cholangitis
  • inflammatory bowel disease
  • polycystic ovary syndrome
  • hereditary haemochromatosis
  • chronic pancreatitis
  • cystic fibrosis
  • alpha-1 antitrypsin deficiency
  • Exclusion Criteria:
  • Patients with:
  • malignant diseases
  • viral hepatitis
  • human immunodeficiency virus
  • contraindications to liver biopsy

About University Of Copenhagen

The University of Copenhagen, a leading research institution in Denmark, is dedicated to advancing medical knowledge and improving patient outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its expertise in various fields, including health sciences, pharmacology, and biotechnology, to design and conduct rigorous clinical studies. Committed to ethical standards and scientific integrity, the University of Copenhagen aims to contribute significantly to the global medical community by facilitating groundbreaking research that addresses pressing healthcare challenges.

Locations

Hvidovre, , Denmark

Patients applied

0 patients applied

Trial Officials

Lise L Gluud, Professor

Principal Investigator

Hvidovre University Hospital

Nicolai J Wewer Albrechtsen, MD, PhD

Principal Investigator

NNF Center for Protein Research

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials